Bogoyavlenskiy Andrey, Alexyuk Pavel, Alexyuk Madina, Berezin Vladimir, Zaitseva Irina, Omirtaeva Elmira, Manakbayeva Adolat, Moldakhanov Yergali, Anarkulova Elmira, Imangazy Anar, Akanova Kuralay, Koshemetov Zhumagali, Orazymbetova Nurkul, Umuraliyev Bakyt
Research and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Scientific Research Institute for Biological Safety Problems, Ministry of Health of Kazakhstan, Almaty 080409, Kazakhstan.
Viruses. 2024 Dec 30;17(1):37. doi: 10.3390/v17010037.
The global burden of COVID-19 continues to rise, and despite significant progress in vaccine development, there remains a critical need for effective treatments for the severe inflammation and acute lung injury associated with SARS-CoV-2 infection. In this study, we explored the antiviral properties of a plant-derived complex consisting of flavonol and hydroxyorganic acid compounds. Our research focused on the ability of the flavonol and hydroxyorganic acid complex to suppress the activity of several key proteins involved in the replication and maturation of SARS-CoV-2. These proteins include ACE2 protein, HRV 3C Protease, and Mpro (Main Protease). It was shown that the plant-based complex effectively inhibited the activity of these viral proteins. In addition to its effects on viral proteins, the flavonol and hydroxyorganic acid complex were shown to suppress viral replication in Vero E6 cells. At a dose of 22 μg/mL, the drug demonstrated maximum antiviral activity, significantly reducing the replication of SARS-CoV-2 in vitro. In preliminary studies, the complex showed both prophylactic and therapeutic potential, suggesting that it may be useful for preventing infection, as well as reducing the severity of disease once an individual has been infected with SARS-CoV-2. Based on the compelling results of this study, we propose the flavonol and hydroxyorganic acid complex as a potential therapeutic compound for SARS-CoV-2. Its ability to inhibit key viral proteins, suppress viral replication and exhibit protective and therapeutic effects positions it as a valuable candidate for further research and clinical evaluation. As the global fight against SARS-CoV-2 continues, plant-based therapies like this complex could complement existing treatments and provide new options for managing and treating the disease.
新型冠状病毒肺炎（COVID-19）的全球负担持续上升，尽管疫苗研发取得了重大进展，但对于与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关的严重炎症和急性肺损伤，仍然迫切需要有效的治疗方法。在本研究中，我们探索了一种由黄酮醇和羟基有机酸化合物组成的植物提取物的抗病毒特性。我们的研究重点是黄酮醇和羟基有机酸复合物抑制几种参与SARS-CoV-2复制和成熟的关键蛋白活性的能力。这些蛋白包括血管紧张素转换酶2（ACE2）蛋白、人鼻病毒3C蛋白酶（HRV 3C Protease）和主要蛋白酶（Mpro）。结果表明，该植物提取物能有效抑制这些病毒蛋白的活性。除了对病毒蛋白的作用外，黄酮醇和羟基有机酸复合物还能抑制Vero E6细胞中的病毒复制。在浓度为22μg/mL时，该药物表现出最大的抗病毒活性，显著降低了SARS-CoV-2在体外的复制。在初步研究中，该复合物显示出预防和治疗潜力，表明它可能有助于预防感染，以及在个体感染SARS-CoV-2后减轻疾病的严重程度。基于本研究令人信服的结果，我们提出黄酮醇和羟基有机酸复合物作为一种潜在的SARS-CoV-2治疗化合物。它能够抑制关键病毒蛋白、抑制病毒复制并表现出保护和治疗作用，使其成为进一步研究和临床评估的有价值候选物。随着全球对抗SARS-CoV-2的斗争仍在继续，像这种复合物这样的植物疗法可以补充现有治疗方法，并为管理和治疗该疾病提供新的选择。
